ClinicalTrials.gg
TerminatedNCT04854434Updated Nov 3, 2023Results posted

A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS Mutations

A Phase 2 interventional study of Selinexor and Pembrolizumab in Metastatic Colorectal Cancer, sponsored by Karyopharm Therapeutics Inc. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
13
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies testing pembrolizumab in Colorectal Neoplasms — 5 open to participants now, 10 under way, 1 of them phase 3. pembrolizumab · Colorectal Neoplasms.

Enrollment
32nd of 33
13 · median 45
Started
2021
with 3 others
Phase 2
19 of 33
4 open now
Registered
24th of 33
by date

Among the 33 studies testing pembrolizumab in Colorectal Neoplasms, this one is the 32nd largest by enrollment, is one of 4 that started in 2021, is one of 19 in phase 2, and was the 24th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

5 of the 33 studies testing pembrolizumab in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies testing pembrolizumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of selinexor alone or with pembrolizumab in participants with advanced or metastatic colorectal cancer (CRC). Approximately 78 participants with advanced or metastatic CRC will be enrolled, and randomized (1:1:1) into three arms A (selinexor only), B (selinexor and pembrolizumab), and C (standard of care [Combination of trifluridine and tipiracil]). Randomization will be based on stratification factors: Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 versus 2. The end of treatment (EoT) visit will occur less than or equal to (\<=30) days post-treatment discontinuation. A survival follow-up visit will be performed every 3 months from EoT and will continue for 12 months.

03

Conditions studied

  • Metastatic Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants have proven diagnosis of unresectable colorectal cancer with a known rat sarcoma (RAS) mutation.
  • Participants have according to 1.1 criteria.
  • Have received 2-3 prior lines of systemic anticancer treatment ( or neoadjuvant therapy is not counted as one ).
  • Participants with stable previously treated are allowed.
  • performance status of 0-2 at the time of screening.
  • Age ≥ 18 years at the time of signing
  • of at least 3 months.
  • Female participants of must agree to use dual methods of and have a negative serum pregnancy test at screening, and male participants must use an effective barrier method of contraception if sexually active throughout the study and for 4 months after the last dose of selinexor or pembrolizumab or 6 months after trifluridine and tipiracil.
  • Written informed consent signed in accordance with federal, local, and institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with a selective inhibitor of nuclear export (SINE) compound or selinexor.
  • Prior treatment with .
  • Participants with microsatellite instability high (MSI-H) or deficient mismatch repair (dMMR).
  • Known allergy to any of study drugs (selinexor, pembrolizumab, and trifluridine and tipiracil) or the of pembrolizumab.
  • Significant cardiovascular impairment, defined as:

    • ≤ 40 percent (%)
    • Active congestive heart failure ( [NYHA]) Class ≥ 3
    • Unstable angina or myocardial infarction within 3 months of enrollment
    • Serious and potentially life-threatening arrhythmia
  • Impaired hematopoietic function (any of the following would result in exclusion):

    • (ANC) less than (\<) 1500/cubic millimeter (mm\^3)
    • count \< 100,000/ mm\^3
    • (Hb) \< 10 gram per deciliter (g/dL)
  • Significant renal impairment, defined as: calculated (CrCl) of \< 30 milliliter per minute (mL/min) using the formula of Cockcroft and Gault.
  • Impaired hepatic function defined as: total greater than (>) 1.5 × (ULN) and (AST) > 2.5 x ULN, AST > 2.5 x ULN; for Arm B, unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin must be ≤ 4 x ULN.
  • Participants with a diagnosis of immunodeficiency or are receiving systemic therapy (>10 mg/day of prednisone or equivalent) or any other form of therapy. Participants with active disease requiring systemic treatment during the past 2 years.

    • Participants with controlled type I and type II diabetes mellitus, and endocrinopathies such as hypothyroidism on stable hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are allowed.

Note: The Investigator needs to evaluate the participants medical history to confirm that they are eligible to receive the combination with pembrolizumab per these criteria.

  • Insufficient time since or not recovered from procedures or anti-cancer therapy, defined as:

    • Not recovered from major surgery ≤ 21 days prior to Day 1 dosing. Minor procedures, such as , dental work, or placement of a port or IV line for infusion are permitted.
    • Have ongoing anti-cancer therapy-related toxicities (CTCAE) Grade > 1. In specific cases, participants whose toxicity has stabilized or with Grade 2 non-hematologic toxicities can be allowed following documented approval by the Sponsor's Medical Monitor.
    • Had last dose of previous anti-cancer therapy ≤14 days prior to Day 1 dosing.
    • Palliative radiotherapy > 14 days prior to the study is allowed.
    • Received drugs in other clinical trials within 28 days, or 5 half-lives of the investigational drug (whichever is shorter), prior to Cycle 1 Day 1 (C1D1).
    • against an infectious disease (e.g., nasal spray influenza vaccine) ≤ 14 days prior to the intended C1D1.
  • Female participants who are pregnant or lactating.
  • Active, ongoing or uncontrolled active infection requiring parenteral antibiotics, antivirals, antifungals within 1 week of Screening.
  • Participants with autoimmune disease, a medical condition that requires systemic corticosteroids or other immunosuppressive medication; or a history of interstitial lung disease.
  • Any gastrointestinal dysfunctions that could interfere with the absorption of selinexor (e.g. bowel obstruction, inability to swallow tablets, malabsorption syndrome, unresolved nausea, vomiting, diarrhea CTCAE > grade 1).
  • In the opinion of the investigator, participants who are below their ideal body weight and would be unduly impacted by changes in their weight.
  • Serious psychiatric or medical conditions that could interfere with participation in the study or in the opinion of the Investigator would make study involvement unreasonably hazardous.
  • Concurrent therapy with approved or investigational anticancer therapeutic including topical therapies.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
13 participants (actual)

Study arms

  • Experimental
    Arm A: Selinexor 80 mg

    Participants received a single dose of selinexor 80 mg (4 tablets of 20 mg) orally QW on Day 1 of each week of a 42-day cycle (i.e., on Days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 33 weeks).

    Drug: Selinexor

  • Experimental
    Arm B: Selinexor 80 mg and Pembrolizumab 400 mg

    Participants received a single dose of selinexor 80 mg (4 tablets of 20 mg) orally QW on Day 1 of each week of a 42-day cycle (i.e., on Days 1, 8, 15, 22, 29, and 36 of each 42-day cycle) in combination with pembrolizumab 400 mg IV once every 6 weeks of each 42-day cycle until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 30 weeks).

    Drug: Selinexor · Drug: Pembrolizumab

  • Active comparator
    Arm C: Standard of care (SOC)

    Participants received combination of trifluridine and tipiracil 35 mg/m\^2/dose tablets orally BID (maximum 80 mg per dose) as SOC on Days 1 through 5 and Days 8 through 12 of each 28-day cycle until PD, intolerable toxicity, or withdrawal from the study (maximum exposure: 11 weeks).

    Drug: Trifluridine · Drug: Tipiracil

Interventions

  • Participants will receive selinexor oral tablets.

    Also known as: Xpovio, KPT-330

  • Participants will receive pembrolizumab intravenously.

    Also known as: Keytruda

  • Participants will receive trifluridine oral tablets as SOC.

  • Participants will receive tipiracil oral tablets as SOC.

06

What researchers measure

Primary outcomes

  1. Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

    PFS was defined as the time from the date of randomization until disease progression or death due to any cause, whichever occurs first. PFS was assessed by the investigator per RECIST 1.1. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: From the date of randomization until disease progression or death, whichever occurs first (up to 8 months)

Secondary outcomes

  1. Arm A, B and C: Overall Survival (OS)

    OS was defined as time from the date of randomization to death due to any cause.

    Time frame: From the date of randomization up to death (up to 8 months)

  2. Arm B and C: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieve complete response (CR) or partial response (PR) or or initiating a new antineoplastic therapy. ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 8 months)

  3. Arm A and C: Overall Response Rate (ORR)

    ORR was defined as the percentage of participants who achieve CR or PR or or initiating a new antineoplastic therapy. ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 8 months)

  4. Arm A, B and C: Progression-free Survival (PFS) at 6 Months

    PFS at 6 months was defined as the time from the date of randomization without disease progression at 6 months as assessed by the investigator per RECIST 1.1. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

    Time frame: At 6 Months

  5. Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 6 Months

    OS was defined as the time from the first dose date to date of death due to any cause. Participant was considered as event (overall survival) free if participant was not died and was alive at 6 months.

    Time frame: At 6 Months

  6. Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 12 Months

    OS was defined as the time from the first dose date to date of death due to any cause. Participant was considered as event (overall survival) free if participant was not died and was alive at 12 months.

    Time frame: At 12 Months

  7. Arm B and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1

    DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first occurrence of CR or PR until disease progression or death, whichever occurs first (up to 8 months)

  8. Arm A and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1

    DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: From first occurrence of CR or PR until disease progression or death, whichever occurs first (up to 8 months)

  9. Arm B and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1

    Disease control rate was defined as participants who achieved best overall response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as assessed by investigator as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study.

    Time frame: From the date of randomization up to death (up to 8 months)

  10. Arm A and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1

    Disease control rate was defined as participants who achieved best overall response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as assessed by investigator as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study.

    Time frame: From the date of randomization up to death (up to 8 months)

  11. Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

    An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

    Time frame: From start of study drug administration up to 12 months

07

Results

Posted Nov 3, 2023
Limitations and caveats
Prior to study completion, the signal was assessed by sponsor to be uncompetitive in the current treatment landscape and thus CRC program was closed. Thereby some of the protocol planned analysis were not performed and thus no data was reported for those outcome measures.

Participant flow

The study was conducted at 3 investigational sites in the United States.

Participant flow — Overall Study
MilestoneArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Started454
Completed010
Not completed444
Withdrew: Death134
Withdrew: Study terminated by sponsor200
Withdrew: Other110

Outcome measures

PrimaryArm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

PFS was defined as the time from the date of randomization until disease progression or death due to any cause, whichever occurs first. PFS was assessed by the investigator per RECIST 1.1. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest sum of the longest diameter (SLD) recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
From the date of randomization until disease progression or death, whichever occurs first (up to 8 months)
Reported as:
Median · Months
Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1
MonthsArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Arm B and C: Progression-free Survival (PFS) as Assessed by the Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1NA (NA to NA)NA (NA to NA)
SecondaryArm A, B and C: Overall Survival (OS)

OS was defined as time from the date of randomization to death due to any cause.

Time frame:
From the date of randomization up to death (up to 8 months)
Reported as:
Median · months
Arm A, B and C: Overall Survival (OS)
monthsArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Arm A, B and C: Overall Survival (OS)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryArm B and C: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieve complete response (CR) or partial response (PR) or or initiating a new antineoplastic therapy. ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 8 months)
Reported as:
Number · percentage of participants
Arm B and C: Overall Response Rate (ORR)
percentage of participantsArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Arm B and C: Overall Response Rate (ORR)0 (NA to NA)0 (NA to NA)
SecondaryArm A and C: Overall Response Rate (ORR)

ORR was defined as the percentage of participants who achieve CR or PR or or initiating a new antineoplastic therapy. ORR was assessed by RECIST 1.1 as defined by the Investigator based on radiologic criteria. Per RECIST 1.1 criteria, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From the date of randomization until the documentation of CR or PR, whichever occurs first (up to 8 months)
Reported as:
Number · percentage of participants
Arm A and C: Overall Response Rate (ORR)
percentage of participantsArm A: Selinexor 80 mgArm C: Standard of Care (SOC)
Arm A and C: Overall Response Rate (ORR)25.0 (0.6 to 80.6)0 (NA to NA)
SecondaryArm A, B and C: Progression-free Survival (PFS) at 6 Months

PFS at 6 months was defined as the time from the date of randomization without disease progression at 6 months as assessed by the investigator per RECIST 1.1. As per RECIST 1.1 criteria, PD was defined as at least a 20% increase in the sum of the longest diameter (SLD), taking as reference the smallest SLD recorded from baseline or the appearance of 1 or more new lesions.

Time frame:
At 6 Months
Reported as:
Median · months
Arm A, B and C: Progression-free Survival (PFS) at 6 Months
monthsArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Arm A, B and C: Progression-free Survival (PFS) at 6 MonthsNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryArm A, B and C: Percentage of Participants With Overall Survival (OS) at 6 Months

OS was defined as the time from the first dose date to date of death due to any cause. Participant was considered as event (overall survival) free if participant was not died and was alive at 6 months.

Time frame:
At 6 Months
Reported as:
Median · percentage of event free participants
Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 6 Months
percentage of event free participantsArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 6 MonthsNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryArm A, B and C: Percentage of Participants With Overall Survival (OS) at 12 Months

OS was defined as the time from the first dose date to date of death due to any cause. Participant was considered as event (overall survival) free if participant was not died and was alive at 12 months.

Time frame:
At 12 Months
Reported as:
Median · percentage of event free participants
Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 12 Months
percentage of event free participantsArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Arm A, B and C: Percentage of Participants With Overall Survival (OS) at 12 MonthsNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryArm B and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1

DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first occurrence of CR or PR until disease progression or death, whichever occurs first (up to 8 months)

No measurements were reported for this outcome.

SecondaryArm A and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1

DOR was defined as the time from first occurrence of CR or PR until the first date of PD per RECIST version 1.1 or death. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) had reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
From first occurrence of CR or PR until disease progression or death, whichever occurs first (up to 8 months)
Reported as:
Median · months
Arm A and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1
monthsArm A: Selinexor 80 mgArm C: Standard of Care (SOC)
Arm A and C: Duration of Response (DOR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1NA (NA to NA)—
SecondaryArm B and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1

Disease control rate was defined as participants who achieved best overall response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as assessed by investigator as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study.

Time frame:
From the date of randomization up to death (up to 8 months)
Reported as:
Number · percentage of participants
Arm B and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1
percentage of participantsArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Arm B and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.140.0 (5.3 to 85.3)—
SecondaryArm A and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1

Disease control rate was defined as participants who achieved best overall response of CR, PR, or at least 12 continuous weeks of stable disease (SD) as assessed by investigator as per RECIST v 1.1. As per RECIST v 1.1 before PD or initiating a new antineoplastic therapy, CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (at least a 20% increase in the sum of diameters of target lesions) taking as reference the smallest sum diameters while on study.

Time frame:
From the date of randomization up to death (up to 8 months)
Reported as:
Number · percentage of participants
Arm A and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1
percentage of participantsArm A: Selinexor 80 mgArm C: Standard of Care (SOC)
Arm A and C: Percentage of Participants With Confirmed Disease Control Rate as Per Response Evaluation Criteria in Solid Tumors Version 1.1100 (NA to NA)—
SecondaryArm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs

An adverse event was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment. A SAE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. A TEAE was defined as those AEs that develop or worsen after the first dose of study drug. TEAEs included both serious and non-serious TEAEs.

Time frame:
From start of study drug administration up to 12 months
Reported as:
Count of participants · Participants
Arm A, B and C: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs
ParticipantsArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
Participants with TEAEs454
Participants with Serious TEAEs120

Adverse events

Collected over From start of study drug administration up to 12 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Selinexor 80 mg1/4 (25%)1/4 (25%)4/4 (100%)
Arm B: Selinexor 80 mg and Pembrolizumab 400 mg3/5 (60%)2/5 (40%)5/5 (100%)
Arm C: Standard of Care (SOC)4/4 (100%)0/4 (0%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
AnaemiaBlood and lymphatic system disorders1/40/50/4
AspirationRespiratory, thoracic and mediastinal disorders0/41/50/4
FallInjury, poisoning and procedural complications0/41/50/4
Most frequent other events
Showing 10 of 68
Most frequent other events
EventArm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)
NauseaGastrointestinal disorders3/44/53/4
FatigueGeneral disorders1/43/53/4
Decreased appetiteMetabolism and nutrition disorders3/42/50/4
DehydrationMetabolism and nutrition disorders1/43/50/4
HyponatraemiaMetabolism and nutrition disorders2/42/51/4
ThrombocytopeniaBlood and lymphatic system disorders2/40/52/4
Abdominal painGastrointestinal disorders0/41/52/4
AnaemiaBlood and lymphatic system disorders2/41/50/4
DiarrhoeaGastrointestinal disorders2/40/51/4
LeukopeniaBlood and lymphatic system disorders1/40/52/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)Total
Mean70.5 ± 3.1161.0 ± 14.7857.0 ± 17.6362.7 ± 13.61
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)Total
Female1416
Male3137
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)Total
Hispanic or Latino1023
Not Hispanic or Latino35210
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Selinexor 80 mgArm B: Selinexor 80 mg and Pembrolizumab 400 mgArm C: Standard of Care (SOC)Total
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1001
White35412
More than one race0000
Unknown or Not Reported0000
08

Study locations

3 sites
  • Valkyrie Clinical Trials
    Los Angeles, California 90067, United States
  • Christiana Care Health Services, Christiana Hospital
    Newark, Delaware 19718, United States
  • BRCR Global
    Plantation, Florida 33322, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Jun 2022, 11 months.

Results were first posted in Nov 2023, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2021
First posted
Apr 22, 2021
StartActual
Jun 29, 2021
Primary completionActual
Jun 24, 2022
CompletionActual
Jun 24, 2022
Results first posted
Nov 3, 2023
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04854434
Responsible party
Sponsor
First posted
Apr 22, 2021
Start date
Jun 29, 2021
Primary completion
Jun 24, 2022
Completion
Jun 24, 2022
Results posted
Nov 3, 2023
Last update
Nov 3, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Selinexor · Pembrolizumab

Start the discussion